吲哚胺2,3二氧化酶在造血干细胞移植的研究进展  

Research Progress of Indoleamine 2,3-Dioxygenase on Hematopoietic Stem Cell Transplantation

作　　者：叶启翔[1] 方建培[1] 

机构地区：[1]中山大学孙逸仙纪念医院儿科,广东广州510120

出　　处：《中华妇幼临床医学杂志（电子版）》2011年第4期296-299,共4页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：国家自然科学基金资助项目(30872383);教育部博士点基金(20090171110064)~~

摘　　要：吲哚胺2,3二氧化酶(indoleamine2,3-dioxygenase,IDO)通过诱导色氨酸分解,调节树突状细胞(dendritic cells,DCs)及T细胞等途径实现造血干细胞移植(hematopoietic stemcell transplantation,HSCT)后诱导T细胞免疫耐受,防止移植物抗宿主病(graft versus host disease,GVHD)的发生及提高移植物存活率。调控吲哚胺2,3二氧化酶已成为提高造血干细胞移植成功率的治疗靶点。Indoleamine 2,3-dioxygenase （IDO）is found could induce T cells immunity tolerance by inducing tryptophan decompose, regulating dendritic cells and T cells and relevant molecular mechanism to prevent graft versus host disease（GVHD）and improve the survive rate of graft. It has became a therapeutic target to improve the success rate of hematopoietic stem cell transplantation（HSCT）.

关 键 词：吲哚胺2 3二氧化酶 造血干细胞移植 免疫耐受 移植物抗宿主病 

分 类 号：R392[医药卫生—免疫学]